Acurx Pharmaceuticals, Inc.
ACXPNASDAQHealthcareBiotechnology
Previous close
$1.47
+$0.02 · +1.38%
ACXP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
49
Fair Value
Momentum
19
Strong Down
Sentiment
54
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAcurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- David Luci
- Listed since
- Jun 25, 2021
- Employees
- 4
Market position
Day range
Current $1.47
52-week range
Current $1.47
- Open
- $1.45
- Previous close
- $1.45
- Volume
- 84.59K
- 0.65× average
- Average volume
- 131.06K
- Average daily volume
- Market cap
- 6.32M USD
- Beta
- -2.03
- Market reference 1
- 50-day average
- $1.5055
- -2.36% below average
- 200-day average
- $2.5794
- -43.01% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -7.55B USD
- P/E (TTM)
- -0.41×
- P/B (TTM)
- 0.77×
- P/S (TTM)
- 0×
- EV / EBITDA
- 948.01×
- Earnings yield
- -213.44%
- Free cash flow yield
- -181855.69%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -151.21%
- Return on assets
- -103.60%
- Return on invested capital
- -153.59%
Financial health
- Debt / equity
- 0×
- Current ratio
- 3.18×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.83B USD | 5.4M USD | 6.04M USD | 4.75M USD | 2.03M USD |
| Selling, general, and administrative | 6.26B USD | 8.7M USD | 8.53M USD | 7.34M USD | 10.78M USD |
| Operating expenses | 8.09M USD | 14.1M USD | 14.58M USD | 12.09M USD | 12.81M USD |
| Interest income | 125.45K USD | — | — | — | — |
| Depreciation and amortization | — | 14.1M USD | — | — | — |
| Operating income | −8.09M USD | −14.1M USD | −14.58M USD | −12.09M USD | −12.81M USD |
| Net income | −7.97M USD | −14.1M USD | −14.58M USD | −12.09M USD | −12.75M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -1046.38%
- 11 comparable reports
- Latest EPS result
- -0.53
- Estimate -0.38 · Miss by 40.71%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
ACXP peers
ETFs holding ACXP
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research ACXPresearch.disclaimer